LBT Innovations Limited (AU:LBT) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Australian medical technology firm LBT Innovations has secured a lucrative deal with AstraZeneca, involving the sale of five APAS® Independence instruments and a seven-year maintenance contract, potentially reaching AU$4.1 million. This agreement, following positive validation studies, highlights the growing commercial interest from large pharmaceutical companies in LBT’s AI-driven microbiology automation technology. The initial installations are slated for the upcoming six months, with expectations of further orders.
For further insights into AU:LBT stock, check out TipRanks’ Stock Analysis page.